Comparative assays for the HER-2/neu oncogene status in breast cancer

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 6, 2004, Pages 627-633

  Vera Román, José María ^a   Rubio Martínez, Luis Alberto ^a  

^a HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER; CHROMOGENIC SUBSTRATE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ANEUPLOIDY; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CHROMOSOME 17; DIAGNOSTIC APPROACH ROUTE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; ONCOGENE NEU; SCORING SYSTEM; ADULT; AGED; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; GENE DOSAGE; GENETICS; HUMAN; MIDDLE AGED; PAGET NIPPLE DISEASE; PROTO ONCOGENE;

ADULT; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOGENIC COMPOUNDS; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE DOSAGE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 4844228676     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
2. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592-1600.
3. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61:1-13.
4. Brennan PJ, Kumogai T, Berezov A, Murali R, Greene MI, Kumogai T. HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene. 2000;19:6093-6101.
5. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19:6102-6114.
6. Hoff ER, Tubbs RR, Myles JL, Procop GW. HER2/neu amplification in breast cancer. Am J Clin Pathol. 2002;117:916-921.
7. Baselga J. Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology. 2001;61:14-21.
8. Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology. 2001;61:73-82.
9. Cell Markers and Cytogenetics Committees, College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med. 2002;126:803-808.
10. Zarbo RJ, Hammond EH. Conference Summary, Strategic Science Symposium: Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003;126:803-808.
11. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS Study. Histopathology. 2003;42:337-347.
12. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19:354-363.
13. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erbB-2) DNA amplification in primary breast carcinoma: interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001;92:2965-2974.
14. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for Trastuzumab therapy: apparent immunohistochemical false-positive do not get the message. J Clin Oncol. 2001;19:2714-2721.
15. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of Topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002;8:1061-1067.
16. Tanner M, Järvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res. 2001;61:5345-5348.
17. van de Vijver MJ, He YD, vant Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
18. Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cel Biol. 2000;20:3210-3223.
19. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assay. J Clin Pathol. 2000;53:374-381.
20. Wang S, Hossein Saboorian H, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15:137-145.
21. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000;13:37-45.
22. Bánkfalvi À, Simon R, Brandt B, et al. Comparative methodological analysis of erbB-2/Her-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissue for diagnostic use. Histopathology. 2000;37:411-419.
23. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-2595.
24. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15:657-665.
25. Gancberg D, Järvinen T, di Leo A, et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat. 2002;74:113-120.
26. Cianciulli AM, Botti C, Coletta AM, et al. Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. Cancer Genet Cytogenet. 2002;133:66-71.
27. Field AS, Chamberlain NL, Tran D, Morey AL. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology. 2001;33:278-282.
28. Hoang MP, Sahin AA, Ordoñez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113:852-859.
29. Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ, Gown AM. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol. 2001;115:814-822.
30. Coutier J, Vincent-Salomon A, Nicolas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol. 2000;13:1238-1243.
31. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873.
32. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157:1467-1472.
33. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R. Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int. 2001;51:579-584.
34. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002;82:1007-1014.
35. Järvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of Topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to Topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
36. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992;89:5321-5325.
37. Glockner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H. Marked intratumoral heterogeneity of c-myc and cyclin D1 but not of c-erbB2 amplification in breast cancer. Lab Invest. 2002;82:1419-1426.
38. Thor A. HER2 - a discussion of testing approaches in the USA. Ann Oncol. 2001;12(suppl 2):S101-S107.
39. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-325.